Join us for the Immuno-Oncology Scientific Symposium on October 16, 2019.
Location: Shanghai, China
Time: 1:30 pm - 4:30 pm with a reception to follow

Return to event page

Registration page coming soon

Conference Agenda

Please note: Agenda times listed are approximate. Doors will open at 1:00 pm for registration.

Time Speaker Topic
1:30-1:50 pm Patrice Hugo Laboratory Considerations for Immuno-Oncology and
Companion Diagnostics Development
1:50- 2:15 pm
Patrick Hurban Integrating Molecular Profiling into Biomarker Strategy
2:15-2:40 pm John Cochran Anatomic Pathology for Developing Biomarkers
for Immuno-Oncology
2:40-3:00 pm
Break
3:00-3:30 pm Mark Edinger Next Generation Immuno-Oncology Flow Cytometry
3:30-4:00 pm Alan Wookey Companion Diagnostics for I-O Clinical Development
4:00-4:30 pm Xiaoxuan Liang
& Haixia Huang
Successful Delivery of IO Biomarkers for Clinical
Development in China

Check back for more information on our topic abstracts.

Speakers:

Patrice Hugo, Ph.D.
Immunology

Dr. Hugo, chief scientific officer at Q2 Solutions, brings more than 25 years of senior scientific leadership experience with extensive management expertise in laboratory operations applied to diagnostics, therapeutic targets and clinical trials. Most recently, Dr. Hugo was Associate vice president and chief scientist at LabCorp/Covance. He has held several other senior leadership positions at companies including Clearstone Central Laboratories, Caprion and PROCREA BioSciences. A noted industry expert, Dr. Hugo has more than 75 scientific publications in internationally renowned journals. He also is active in a number of industry organizations, including his role on the Board of Directors for the non-for-profit Personalized Medicine Partnership for Cancer in Quebec, Warnex, offering analytical and bioanalytical services and his role as a Steering Committee Member for the Biomarker Factory.

Dr. Hugo obtained a Ph.D. at McGill University and completed five years of post- doctoral fellowship at the Walter Elisa Hall Institute in Australia, and Howard Hughes Medical Institute.

Patrick Hurban, Ph.D.
Genomics

Dr. Hurban is senior director and global head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes. Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.
Following a Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill, he earned his Ph.D. in human genetics from the University of Utah in Salt Lake City before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University. 

John Cochran, M.D., FCAP
Pathology

Dr. John Cochran is the Chief Pathologist at Q2 Solutions, where he leads an experienced global team of Pathologists and provides strategic vision to the company. He has over 20 years of pathology experience and vast knowledge of the clinical trial industry. Previously, Dr. Cochran was CEO and founder of Chestatee Pathology Associates, a pathology private practice with contractual relationships for professional laboratory management. Prior to that, he was Medical Director at Pathology Lab in Georgia. Dr. Cochran has served as a managing consultant to Emory Specialty Associates, Division of Pathology, the private practice arm of the Department of Pathology at Emory University. In addition, he was a consultant to numerous wealth management firms worldwide on healthcare investments, as well as to internet-based medical content providers on subjects involving the pathologic basis of disease.

After receiving his undergraduate degree from Emory University, Dr. Cochran graduated from the Emory University School of Medicine. He also completed his residency at Emory University School of Medicine. Dr. Cochran is board certified by the American Board of Pathologists.

Mark EdingerMark Edinger
Flow Cytometry

Mark Edinger is the scientific advisor for flow cytometry at Q2 Solutions, and is responsible for flow cytometry assay design and implementation. He works with both the Translational Biomarkers Laboratory to develop assays and the Global Cytometry Group to produce assays, and he is the architect of the systems and workflows used in Q2 Solutions’ flow cytometry assay development and production laboratories. Mark joined Quintiles in 2012 and was part of a collaboration which introduced the quantitative standardization of flow cytometers, along with other state of the art practices, making Quintiles flow laboratories the first to offer this level of instrument standardization anywhere in the world. Previously, he worked at Becton Dickinson (BD) where he founded the Technical Applications Group, and later the R&D Systems Validation Laboratory. While at BD, Mark worked with scientists at Amgen to develop the whole blood phosphoprotein lysing buffer that is now used daily in laboratories throughout the world. Mark began his career at the Cleveland Clinic Foundation, a preeminent medical institution, where he pioneered flow cytometry in the late 1970s, building both clinical and research core flow cytometry laboratories. While there, he developed many of the techniques and assays employed today for clinical practice and academic research. During this time, Mark also was a consultant for BD Immunocytometry Systems and participated in clinical trials of new BD products.

Mark graduated from Case Western Reserve University with a Bachelor of Science degree in biology.

Alan Wookey
Companion Diagnostics, Oncology

Alan Wookey is the global science lead for companion diagnostics, and the scientific advisor for oncology. He leads business development and scientific strategy for the companion diagnostics and oncology service offerings. He also provides expert consultation in a number of areas including science and technologies, regulatory and management. Prior to joining Q2 Solutions, he served as director and head of the oncology biomarker group at AstraZeneca where he initiated the company’s personalized medicine and pharmacogenetics efforts, as well as its clinical biomarkers group. During his 20+year career, Alan also served as associate vice president, global head of companion diagnostics, of LabCorp Clinical Trials (now Covance).

Alan earned Bachelor of Science degrees in life sciences and microbiology from the University of Liverpool, and a Post Graduate Diploma in management studies from Manchester Metropolitan University.

Xiaoxuan LiangXiaoxuan Liang, Ph.D.
Biomarker Liaison, Oncology

Dr. Liang works as a biomarker liaison leading early engagement and communication between biomarker scientists and clinical scientists to provide input in tests, platforms and associated technical aspects of the trials. She supports feasibility discussions concerning assay transfer and test validation to ensure biomarker method fit the study requirements including new technology evaluation. Dr. Liang coordinates scientific activities across the Q2 Solutions laboratory network with the Scientific Advisors. Before going into industry, she was a research assistant in MD Anderson Cancer Center, Department of Immunology/Melanoma, supporting the studies on mechanisms of the resistance of immunotherapy caused by genetic aberrations and TME factors, testing different combination treatments using different in vivo tumor models (Melanoma). After that, Dr. Liang joined WuXi Diagnostics as a senior scientists and was responsible for IVD/CDx development and registration.

Haixia HuangHaixia Huang, M.D., MLS
Clinical Lab Science and Molecular Biology

Dr. Haixia Huang is the Medical Director of Q2 Solutions for Beijing and Mumbai. She oversees the regional central laboratory services for clinical trials, with a main focus on scientific and medical support to clients, innovative and top-notch laboratory solutions, and in-depth discussions in study strategy and design. Dr Huang has extensive experiences in quality improvement of clinical laboratory services and technical development with strong background in cellular and molecular genetics for both research and clinical settings. Previously, Dr Huang was the central lab director of National Clinical Research Center and KingMed Diagnostics, Shanghai. She is licensed in clinical laboratory science in both the US and China. 

Dr Huang obtained her doctorate degree in Medicine at Shanghai Jiao Tong University School of Medicine, and completed six years of post- doctoral fellowship at the California Institute of Technology.